Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.40 |
| ▸ | MAT2A | P31153 | 4/20 | 0.35 |
| ▸ | COMT | P21964 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2596807 | 0.80 | JAK2 (0.32) | TGFBR1 | |
| SCHEMBL2596979 | 0.78 | TGFBR1 (0.41) | TGFBR1MAT2A | |
| SCHEMBL27022336 | 0.77 | TGFBR1 (0.39) | TGFBR1MAT2ACOMTKDM4EALDH1A1 | |
| SCHEMBL2596805 | 0.76 | CCNK (0.41) | MAT2ATP53KDM4EALDH1A1MAPT | |
| SCHEMBL2596945 | 0.71 | ALDH1A1 (0.38) | TP53KDM4EALDH1A1GAAMAPT | |
| SCHEMBL2596946 | 0.71 | ALDH1A1 (0.38) | TP53KDM4EALDH1A1GAAMAPT | |
| SCHEMBL2596815 | 0.70 | KDM4C (0.39) | KDM4EALDH1A1GLAGAAMAPT | |
| SCHEMBL12725097 | 0.70 | ENPP1 (0.36) | TGFBR1MAT2ATP53ALDH1A1MAPT | |
| SCHEMBL29586047 | 0.68 | COMT (0.35) | TGFBR1COMTKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL2596776 | 0.68 | TGFBR1 (0.36) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073918-B2 | Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130324528-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-05 | — | — | US | disclosed |
| WO-2011146287-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324528-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | ALK, ALKBH5, ALKBH3 | TGFBR1 413/4885MAT2A 2421/4885COMT 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.